Although new agents have demonstrated benefit in the treatment of patients with advanced pancreatic neoplasms, outcomes remain poor, said Paul E. Oberstein, MD. In the United States, about 50% of patients with metastatic pancreatic adenocarcinoma will die within 2 months of diagnosis. Additionally, 50% of elderly patients never receive any therapy.
In a presentation at the 2018 OncLive® State of the Science Summit™ on Gastrointestinal Cancers, Oberstein, director of Gastrointestinal Medical Oncology at NYU Langone’s Perlmutter Cancer Center, discussed incorporating novel agents and sequencing approaches in advanced pancreatic neoplasms. Read more . . .